This is a contrast between Capricor Therapeutics Inc. (NASDAQ:CAPR) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) based on their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Capricor Therapeutics Inc.||1.67M||8.84||15.19M||-0.11||0.00|
|Adverum Biotechnologies Inc.||1.40M||299.25||69.92M||-1.04||0.00|
Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.
Table 2 has Capricor Therapeutics Inc. and Adverum Biotechnologies Inc.’s return on assets, net margins and return on equity.
|Net Margins||Return on Equity||Return on Assets|
|Capricor Therapeutics Inc.||-909.58%||3.9%||2.6%|
|Adverum Biotechnologies Inc.||-4,994.29%||-32.7%||-30.8%|
Risk & Volatility
Capricor Therapeutics Inc. has a beta of 1.5 and its 50.00% more volatile than Standard & Poor’s 500. Adverum Biotechnologies Inc.’s 219.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 3.19 beta.
The current Quick Ratio of Capricor Therapeutics Inc. is 6.1 while its Current Ratio is 6.1. Meanwhile, Adverum Biotechnologies Inc. has a Current Ratio of 22.1 while its Quick Ratio is 22.1. Adverum Biotechnologies Inc. is better positioned to pay off its short-term and long-term debts than Capricor Therapeutics Inc.
The next table highlights the shown recommendations and ratings for Capricor Therapeutics Inc. and Adverum Biotechnologies Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Capricor Therapeutics Inc.||0||0||1||3.00|
|Adverum Biotechnologies Inc.||0||0||0||0.00|
Capricor Therapeutics Inc.’s upside potential currently stands at 717.76% and an $3.5 consensus price target.
Institutional & Insider Ownership
Institutional investors owned 5.4% of Capricor Therapeutics Inc. shares and 74.3% of Adverum Biotechnologies Inc. shares. Insiders owned 35.68% of Capricor Therapeutics Inc. shares. Comparatively, 6.43% are Adverum Biotechnologies Inc.’s share owned by insiders.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Capricor Therapeutics Inc.||11.49%||-4.62%||-40.85%||-59.58%||-71.97%||18.29%|
|Adverum Biotechnologies Inc.||14.42%||54.72%||33.33%||-19.67%||-26.02%||56.19%|
For the past year Capricor Therapeutics Inc. has weaker performance than Adverum Biotechnologies Inc.
Capricor Therapeutics Inc. beats on 8 of the 11 factors Adverum Biotechnologies Inc.
Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The companyÂ’s development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.